Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6623 Download: 247 Web of Science: 4 Crossref: 5

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 1694 Download: 194 Web of Science: 2 Crossref: 5

Letter to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai

Clin Mol Hepatol. 2025;31(3):e247-e248. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2025.0073

View: 746 Download: 37

Correspondence

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815

View: 1382 Download: 30

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2024;30(4):989-991. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0705

View: 1455 Download: 50 Crossref: 1

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 4979 Download: 227 Web of Science: 19 Crossref: 21

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 5394 Download: 145 Web of Science: 7 Crossref: 8

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 6757 Download: 274 Web of Science: 18 Crossref: 19

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 6612 Download: 267 Web of Science: 32 Crossref: 33

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 7974 Download: 246 Web of Science: 20 Crossref: 19

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 6988 Download: 273 Web of Science: 44 Crossref: 49

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 9046 Download: 315 Web of Science: 31 Crossref: 35

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 21466 Download: 694 Web of Science: 311 Crossref: 348

Editorial

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?

Eugene Han, Yong-ho Lee

Clin Mol Hepatol. 2023;29(4):980-983. Published online August 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0250

View: 3561 Download: 120 Web of Science: 3 Crossref: 4

Special Review

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0291

View: 4360 Download: 188 Web of Science: 37 Crossref: 42

Original Article

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330

View: 5630 Download: 212 Web of Science: 20 Crossref: 23

Editorial

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 4002 Download: 79 Web of Science: 4 Crossref: 3

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 4420 Download: 88 Web of Science: 3 Crossref: 3

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 3991 Download: 122 Web of Science: 2 Crossref: 1

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 3958 Download: 77 Web of Science: 7 Crossref: 8

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 6087 Download: 158 Web of Science: 11 Crossref: 9

Original Article

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 10380 Download: 462 Web of Science: 33 Crossref: 35

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 3691 Download: 74

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 4157 Download: 89 Web of Science: 4 Crossref: 5

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 9703 Download: 539 Web of Science: 51 Crossref: 51

Original Article

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

Clin Mol Hepatol. 2022;28(3):497-509. Published online April 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0019

View: 7577 Download: 183 Web of Science: 9 Crossref: 8

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng

Clin Mol Hepatol. 2022;28(3):483-496. Published online March 2, 2022

DOI: https://doi.org/10.3350/cmh.2021.0406

View: 10203 Download: 299 Web of Science: 66 Crossref: 70

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 4285 Download: 96

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 5063 Download: 112 Web of Science: 2 Crossref: 2

Review

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

View: 11049 Download: 423 Web of Science: 16 Crossref: 17

1 | 2 |

Viewed By 12461	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7606	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7052	MAFLD: How is it different from NAFLD?
Viewed By 5653	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5517	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search